Table 1.
Patient characteristics
| Characteristics | Number of patients |
|---|---|
| Total number of patients | 58 |
| Age at transplantation (years)a | 7.4 (0.8–17.3) |
| Sex (females:males) | 23:35 |
| FAB classification at diagnosis | |
| M1/M2 | 14/7 |
| M3/M4/M5 | 5/13/5 |
| M6/M7 | 3/11 |
| Cytogenetics at transplantationb | |
| Normal | 27 |
| Favorable | 1 |
| Unfavorable | 9 |
| Indeterminate | 21 |
| EMDc | |
| Isolated CNS | 8 |
| Other sites±CNS | 14 |
| High disease burdend | |
| Presence of circulating blasts | 29 |
| ≥25% marrow blasts | 21 |
| Phase of disease at transplantation | |
| Second remission | 12 |
| Untreated first relapse | 11 |
| Refractory disease | 35 |
| Months from diagnosis to transplantationa | 7.9 (1.9–54.7) |
| Donor type | |
| HLA-identical related | 19 |
| Mismatched related | 17 |
| Unrelated | 22 |
| CMV serology | |
| (+) recipient/(±) donor | 29 |
| (−) recipient/(+) donor | 10 |
| (−) recipient/(−) donor | 19 |
| Preparative regimen | |
| Non-TBI containing | 9 |
| TBI-containing | 49 |
| GVHD prophylaxis | |
| Methotrexate alone | 13 |
| Cyclosporine and methotrexate | 45 |
| Marrow cell dose (cells × 108/kg)a | 4.4 (1.1–15.6) |
a
Data are median (range).
b
Cytogenetics was classified as favorable if t(8;21), t(15;17) or inversion 16 was present, unfavorable if involving 11q23 abnormalities or monosomy 7, and indeterminate for all other abnormalities.14,24
c
Refers to EMD at any time prior to transplantation.
d
Defined as presence of circulating blasts or ≥25% marrow blasts in patients with untreated first relapse or refractory disease (n = 34/46).